| Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
|
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
|
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Paroxysmal Nocturnal Hemoglobinuria |
|
StatPearls |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53 |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Transfusion Support of Patients with Myelodysplastic Syndromes |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
